Summary of Significant Accounting Policies (Details Narrative) - USD ($) |
1 Months Ended | 12 Months Ended | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Feb. 27, 2020 |
Jan. 30, 2020 |
Sep. 30, 2019 |
Aug. 31, 2019 |
May 31, 2019 |
Mar. 31, 2019 |
Jun. 30, 2018 |
Apr. 30, 2018 |
Jan. 31, 2018 |
Dec. 31, 2019 |
Dec. 31, 2018 |
|
| Proceeds form public offering of equity securities | $ 148,800 | $ 1,971,000 | $ 515,000 | $ 1,679,230 | $ 2,068,900 | $ 877,500 | |||||
| Income tax interest and penalties | |||||||||||
| Allowance for doubtful accounts receivable | |||||||||||
| Finite-lived intangible asset, useful life | 17 years | ||||||||||
| Research and development costs | $ 647,994 | $ 493,410 | |||||||||
| Dental Patents [Member] | |||||||||||
| Write off intangible asset | $ 50,255 | ||||||||||
| PrintRite3D [Member] | |||||||||||
| Write off intangible asset | 23,909 | ||||||||||
| March 15, 2019 [Member] | |||||||||||
| Proceeds form public offering of equity securities | $ 1,679,230 | ||||||||||
| Subsequent Event [Member] | |||||||||||
| Reverse stock split, description | 1-for-10 basis | ||||||||||
| Proceeds form public offering of equity securities | $ 1,711,124 | ||||||||||
| X | ||||||||||
- Definition Write off intangible asset. No definition available.
|
| X | ||||||||||
- Definition Amount of allowance for credit loss on accounts receivable. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. No definition available.
|
| X | ||||||||||
- Definition The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The cash inflow associated with the amount received from entity's first offering of stock to the public. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|